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reservations have restricted market access thus increasing co-pays. This is driven 
by stakeholder concerns on non-compliance leading to drug resistance, promiscuity, 
and development off a false sense of security resulting in a drop in HIV screening 
rates and protective measures. The gravity of the issue is judged by the fact that, 
FDA has called for a REMS to take care of these issues. ConClusions: The utiliza-
tion of a new medical service is impacted by societal perceptions, especially those 
conflicting with general values. In spite of regulatory approvals and national recom-
mendations supported by clinical evidences, low adoption and high co-pays reflects 
that the market access is significantly driven by strong prevailing societal views.
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objeCtives: Two human papillomavirus (HPV) vaccines were licensed to prevent 
HPV infections, but the utilization remains low in the United States (US). Previous 
trend studies about HPV vaccine utilization in the US are scarce and their conclusions 
are subject to internal invalidities due to methodological flaws. This study aimed to 
reinvestigate the trend of HPV vaccine utilization including uptake, completion, and 
adherence by using more accurate measurement and sophisticated statistical meth-
ods. Methods: This was a retrospective cross-sectional study. Subjects aged 11-32 
in the National Health and Nutrition Examination Survey 2011-2012 were extracted. 
Two constructs of the Andersen healthcare utilization model were adapted for vari-
ables selection. Heckman two-step sample selection models along with logistic and 
Poission regressions were performed to examine variables associated with vaccine 
uptake, completion, and adherence. Results: Among study subjects (weighted N= 
92,290,848), 19.7% were HPV vaccine users. Factors positively related to vaccine uptake 
included being female, younger age, going to a doctor’s office or hospital for most 
healthcare services, and having Medicaid or other public insurance. Among HPV vac-
cine users, higher income was positively related to vaccine completion and adher-
ence. Vaccine completion rate did not increase overtime. Nonetheless, subjects who 
received their first dose of HPV vaccine between 2008 to 2010 had better adherence, 
compared with subjects who received their first dose in 2006, the vaccine introduc-
tion year. ConClusions: We observed disparities in HPV vaccine uptake, indicating 
that expanding insurance coverage to HPV vaccine and increasing vaccine access 
through primary care services could be efficient ways to improve the low HPV vaccine 
initiation rate in the US. Additionally, the increasing trend of HPV vaccine utiliza-
tion observed from previous studies could be mistaken due to secular accumulation 
overtime. Because the vaccine completion rate actually did not increase over time, 
more efforts should be addressed to ensure vaccine completion.
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objeCtives: Vaccines are one of the greatest triumphs of healthcare innovation. 
They have saved millions of lives, prevented destructive chronic illnesses and eased 
pressures on health services across the globe. However, it is surprisingly difficult 
for manufacturers trying to navigate the UK government system. We provide an 
outline of the route to potential reimbursement, using recent examples, and guid-
ance based on lessons learned. Methods: Published UK articles, The Health and 
Social Care Act 2012 and government and industry records were scrutinised and 
summarised into an outline of the process to make vaccines available. Examples of 
vaccines, the challenges they have faced and potential solutions to those challenges 
were examined. Results: Once a licence has been obtained, usually through the 
European Medicines Agency, the Joint Committee on Vaccination and Immunisation 
(JCVI), makes recommendations to the Department of Health (DH). The JCVI covers 
all UK countries (subject to potential devolution of powers to Scotland). The JCVI is 
considering allowing industry to attend Committee meetings, which would be a 
huge step forward for such a secretive body. There is no scoping phase, limited stake-
holder engagement; recommendations are not made public and their rationale not 
given, and there is no appeal element to the process. The DH agrees the price of each 
vaccine, which in a recent example took around a year, with input from NHS England 
(NHSE) and Public Health England (PHE). PHE is then responsible for implementation 
and procurement through its Health Protection Directorate. To draw together this 
process, the NHSE and DH jointly convene a Senior Oversight Committee, chaired 
by NHSE. ConClusions: Companies proposing to bring vaccines to market need 
to pay special attention, well in advance, to navigating this complicated structure. 
This is needed to achieve a satisfactory price, which rewards R&D and other costs, 
within a reasonable period.
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objeCtives: Incentivizing antibiotic development in advance of resistance devel-
opment is a critical global health policy issue. A number of policy initiatives are 
under development globally. Some focus on alternative reward mechanisms inclu-
sive of lump sum payments; others focus on enhanced reimbursement once the 
drugs reach market. Understanding how the timing and magnitude of the rewards 
impact antibiotic R&D investment decisions is essential to effective and efficient 
policy development. Methods: The R&D portfolio investment decision process and 
anticipated cash flow for antibiotics is modeled using decision trees composed of 
deterministic decision nodes and probabilistic uncertainties. (e.g., the probability 
of success during phase 2 trials). Monte Carlo simulations and calculations for net 
present values and the decision options at the various nodes are incorporated into 
the decision tree analysis in order to provide insights into the valuations at the vari-
availability of novel 2GDAAs. Treatment patterns are sensitive to market entry of 
new HCV medications. HCV treatment selection and duration may be influenced 
by disease severity and treatment history.
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objeCtives: Cachexia is characterized by a loss in muscle mass leading to an overall 
reduction in function and is often related to severe chronic conditions such as can-
cer, kidney disease and HIV. Anabolic steroids (AS) have been seen as a potential aid 
to reducing the impact of cachexia in HIV patients, but AS therapy remains contro-
versial. The purpose of this study was to characterize HIV related cachexia patients 
and look for differences between those treated or not treated with AS. Methods: 
To complete this study we used Medicare LDS 5% random sample for 2011-2013. 
Patients were identified as having HIV (ICD-9 code 042) and then cachexia (ICD-9 
code 799.4, 783.0, 783.2, and 783.3) using inpatient and outpatient claims. AS treat-
ment was identified using HCPCS J codes. Among those with cachexia, patients 
receiving AS were compared to those who were not using frequencies, means, t-test, 
and chi-square statistics. Results: There were over 4,000 HIV patients in the sam-
ple, 1,835 of which had cachexia. Only 54 patients received AS therapy, but there 
were still differences between treated and non-treated patients in terms of gender 
(90.74% and 72.09%, respectively, p= 0.01) and race (66.67% and 45.65%, respectively, 
p= 0.03). Treated patients had higher CCI scores (11.72 versus 9.75, p= 0.01). In each 
group 75% of individuals received Medicare benefits because of chronic disability. 
Treated and untreated patients had similar ER and inpatient visits as well as simi-
lar total costs ($43,085.76 versus $29,930.82, inpatient, p= 0.07). ConClusions: In 
this study we have seen that in HIV related cachexia those patients who receive AS 
therapy for cachexia are the most severe of an already severely ill group. This study 
indicates that AS treatment is being used as a last resort instead of earlier in the 
cachexic process when the treatment could potentially have a larger impact on a 
patient’s disease progression.
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objeCtives: Over 100,000 people in the UK are living with human immuno-
deficiency virus (HIV). This once acute condition has been transformed into a 
near chronic condition by antiretroviral treatment (ART), providing people living 
with HIV (PLHIV) remain virologically suppressed. In order to maintain suppres-
sion, patients must adhere to ART. Single tablet ART regimens (STRs) are a recent 
advance aimed at improving adherence. However, PLHIV are more likely to develop 
non-AIDS related morbidities (NARMs) including diabetes and chronic kidney 
disease than the general population. Our objective was to develop a HIV model 
with the ability to capture adherence and NARMs, suitable for health technology 
assessments. Methods: A review of HIV models concluded that existing models 
do not adequately account for either adherence benefits associated with STRs or 
the impact of non-AIDS related morbidities. We developed an individual patient 
simulation model in R to predict clinical and economic outcomes of ART in treat-
ment naïve patients. Patients move through a clinically validated treatment path-
way based on previous treatments and standard of care. The probability of viral 
suppression at 48 weeks for each antiretroviral treatment, informed by a recent 
network meta-analysis, determines whether CD4 levels will increase or decrease. 
The level of CD4, along with patient’s characteristics and current antiretroviral 
treatment, are used to predict NARMs, opportunistic infections and morbidities. 
Adherence to treatment modifies the long term probability of remaining virologi-
cally suppressed. Results: Our model predicts overall survival, CD4 over time 
and event rates that concur with long term studies in HIV. The model also predicts 
other clinical and economic outcomes including time on first treatment, QALYs 
and cost, stratified by resource category. ConClusions: This model is the first, 
to our knowledge, to incorporate the adherence benefit of STRs and the impact of 
NARMs on estimates of cost-effectiveness of ART in HIV.
PIN99
THe ImPacT of socIeTal vIews oN markeT access- case sTUdIes 
for UTIlIzaTIoN of HPv vaccINes IN cervIcal caNcer aNd PreP HIv 
PreveNTIve THeraPy
Staples O1, Sanyal S2, Khatura N2, Mishra A2, Kumar A1
1ZS Associates, London, UK, 2ZS Associates, New Delhi, India
objeCtives: Studies in literature have shown that the rates of awareness, intent 
and use of HPV vaccines and HIV preventive therapies rose during first years of 
launch but have dropped subsequently. The objective of this study is to assess the 
impact of social and behavioral factors on the acceptance and usage of these thera-
pies. Methods: A detailed review of medical literature, journals, regulatory publi-
cations, and physician blogs on HPV and HIV preventive therapies was conducted. 
Our research has been structured by exemplifying two case studies assessing the 
impact of stakeholders’ opinions on acceptance and adoption of vaccines and pre-
ventive therapies Results: Case study 1 Although EMEA approved HPV vaccines 
in 2006, their coverage remains suboptimal. These vaccines continue to have low 
adoption throughout Europe, compared to other adult vaccines. This is attribut-
able to apprehensive views among stakeholders, such as parents, having concerns 
on promiscuity and vaccine safety. Similar views were observed among European 
press and religious groups. The attitude of physicians also had a nebulous outlook, 
impacting adoption. Case study 2 A similar scenario exists in the US, with PrEP 
HIV preventive therapy. Although medical literature supports the therapy, societal 
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tion prescribed between July 2013 and June 2014. Results: Of 2,558 CHC treated 
patients, 142 patients (5.6%) were identified as having CKD . The mean age of CHC 
patients with CKD was 61 years compared to 57 years among those without CKD 
(p< .0001). Compared to CHC patients without CKD (n = 2,416), patients with CKD had 
significantly more comorbidities including diabetes (53% vs 23%, p< .0001), major 
depression (15% vs.6%, p= .0007), hypertension (85% vs. 51%, p< .0001) and heart 
failure (19% vs. 2%, p< .0001). CHC patients with CKD also had higher prevalence 
of kidney transplants (11% vs.1%, p< .0001) and more liver transplants (35% vs. 6%, 
p< .0001). For concomitant drug use, CHC patients with CKD had significantly more 
concomitant drugs (by drug class) during the 2-year baseline period compared to 
those without CKD (17 vs 11, p< .0001). Average annual out-of-pocket pharmacy 
expenses at baseline were significantly higher among CHC patients with CKD com-
pared to those without CKD ($1,079 vs. $606, p< .0001). ConClusions: In a US 
commercially insured population, treated CHC patients with CKD had significantly 
higher rates of comorbidities and drug utilization compared to those without CKD.
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objeCtives: To assess adherence in clinical practice of HIV patients switching to 
emtricitabina+tenofovir disoproxil+rilpivirin Methods: An observational retro-
spective cohort analysis, based on administrative databases from four Italian LHUs. 
The date of the first prescription of emtricitabina+tenofovir disoproxil+rilpivirin 
between January, 2010 and December, 2013 has been used as the index date. Patients 
were characterized back in previous 12 months to assess HIV treatments, and fol-
lowed up after index date for 12 months, date of death, or exiting the database 
(whatever came first). Non-adherence, as well as selective non-adherence, to antiret-
roviral medications were calculated using pharmacy refill compliance data in pre/
post index date period. Non-adherence measures were expressed in percentages of 
days spent either without all prescribed antiretrovirals (complete non-adherence) 
or without at least one of the prescribed regimen components (selective non-
adherence) on total days prescribed Results: During the observation period, 87 
patients switched to emtricitabina+tenofovir disoproxil+rilpivirin: 10 from Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), 62 from efavirenz+emtricita
bina+tenofovir disoproxil (EFV/TDF/FTC) and 15 from Protease Inhibitors (PIs). Post-
switch non-adherence among the 87 patients switching to emtricitabina+tenofovir 
disoproxil+rilpivirin was around 4%, with small differences according to previous 
anti-retroviral therapies (4.7% in previously NNRTIs-treated, 4.2% in efavirenz+em
tricitabina+tenofovir disoproxil group and 3.2% in patients with previous PIs). For 
all of them, pre-switch non-adherence showed much higher values: from NNRTIs 
20.8% selective non-adherence, 30.5% to all drugs; from EFV/TDF/FTC 10.7%; from 
PIs 14.2% selective, 25.8% to all ConClusions: In this preliminary analysis, switch-
ing to emtricitabina+tenofovir disoproxil+rilpivirin increased treatment adherence 
with respect to previous therapies. This phenomenon was highly evident in patients 
coming from NNRTIs and PIs, who reported an absolute decrease in non-adherence 
rates of 46.6% and 36.8%, respectively
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objeCtives: The aim of this study is to determinate the minimum indicators to 
evaluate management and clinical results in institutions assisting patients living 
with HIV in Colombia, between different actors of the Health System. Methods: 
The Colombian Association of Infectology, health insurance companies, govern-
mental entities, international agencies and professionals leaders in attention of HIV 
patients were invited in order to have a consensus. Literature research in different 
databases like PubMed, Embase and Cochrane using Mesh terms was used. 3.023 
articles were found. After reading the titles 414 articles were selected, but finally 20 
articles were included. Experts reviewed the articles and raised indicators, then all 
system actors, selected the final indicators. Results: 17 indicators were selected 
and then classified in 4 groups. In the initial evaluation indicators included the 
proportion of patients with diagnosis of HIV who had attention with expert doc-
tors, patients with report of CD4, patients with viral load and patients with report 
of Lymphocytes. Monitoring indicators included the proportion of people with 
annual PPD, people with report of CD4 and viral load in the last 6 month, patients 
with annual syphilis screening and patients with cardiovascular risk assessment. 
Therapy indicators included the proportion of pregnant using anti-retroviral agents, 
patients with antitubercular agents. Furthermore, proportion of HIV people with 
undetectable viral load in the 48 weeks or more since the beginning of the treatment 
with antiretroviral agents, and others. Finally, the specific prevention indicators 
were related with people with latent tuberculosis treatment, prophylaxis for pneu-
monia by Pneumocystis Jirovecii and a proportion of people with complete vaccina-
tion schedule for Hepatitis B. ConClusions: Formulating indicators to institutions 
assisting patients living with HIV could decrease health inequalities in the attention 
of this population and will have a positive impact in HIV patients health results.
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ous stages. We perform sensitivity analysis in order to understand the attractiveness 
of various incentive schemes. Results: Once antibiotic development has success-
fully moved past the pre-clinical stages, incentives appear to not have all that much 
influence on investment decisions. At the pre-clinical stage, however, investment 
decisions are sensitive to incentives. Out of the incentives assessed, those rewarding 
success at the pre-clinical stage are the most effective at encouraging pre-clinical 
development. Incentives given further downstream are less attractive to develop-
ers due to the magnitude of upfront expenditure; the time value of money and 
associated development risks. ConClusions: A decision option approach to the 
valuation of antibiotics allows for a clear understanding of the value throughout the 
development cycle and allows us to assess the best structure for incentives aimed 
at encouraging antibiotic development.
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objeCtives: The aim of our examination was to evaluate knowledge of educated 
nurses on the prevention of infections due to inappropriate decontamination of 
nursing tools and patient environments and on nosocomialis infections and infec-
tion control. Methods: We carried out our cross-sectional, quantitative examina-
tion between 1.12.2014 and 28.02.2015 in 12 inpatient wards of a county hospital in 
Hungary. Our participants were educated nurses (N= 103), and for data collection we 
used two questionnaires: one with only closed-ended questions and one with only 
open-ended questions. We used Microsoft Office Excel 2002 software to carry out 
descriptive statistics, χ 2-test and two-sample t-test (p< 0.05). Results: On average, 
nurses scored higher in case of the questionnaire with closed-ended question that 
in case of the questionnaire with open-ended questions (p= 0.021). Average scores of 
nurses working at an intensive care ward was significantly higher than nurses work-
ing at other wards (p< 0.001). Nurses working in health care for longer time find the 
prevention of nosocomialis infections more important (p< 0.05). We found significant 
difference in case of the preparatory board, the PC keyboard, the patient’s bedside 
table, the telephone and the nurse-bell (p< 0.05), unlike in case of the door handle 
(p= 0.081). ConClusions: Knowledge of nurses on nosocomialis infections is not 
satisfactory at all fields. Nosocomialis infections occur the most often at intensive 
care wards, thus nurses working at that ward have the most extensive knowledge 
on the topic. Participants scored higher in case of the closed-ended questionnaire 
and chose the best answer more easily. Nurses do not consider the infectedness 
of the patient- or working environment highly important, although the play and 
important role in transferring nosocomialis infections.
PIN104
descrIPTIve aNalysIs of drUg UTIlIzaTIoN amoNg cHroNIc HePaTITIs c 
vIrUs (cHc) PaTIeNTs IN THe Us commercIally INsUred PoPUlaTIoN
Puenpatom A1, Zhang D2, Burrell E1, Nwankwo C3
1Merck & Co., Inc., North Wales, PA, USA, 2Merck & Co., Inc., West Point, PA, USA, 3Merck & Co., 
Inc., Kenilworth, NJ, USA
objeCtives: This study described patient characteristics and real world drug utili-
zation among patients diagnosed with CHC in the US. Methods: We conducted a 
retrospective database study using the Truven Health MarketScan® database. Patients 
were identified with ≥ 2 HCV medical claims (ICD-9: 070.54, 070.44, 070.70, 070.71) 
≥ 1 month apart (to define chronic illness), and had 3-year continuous enrollment 
in order to capture treatment experience. The CHC treated cohort was defined as 
those who had ≥ 1 HCV medication filled from 7/1/2013 to 30/6/2014. Results: 
Compared to untreated patients (n = 13,953), CHC treated patients (2,558) had a 
higher prevalence of liver transplants (7% vs 3%, p< .0001), cirrhosis (40% vs 20%, 
p< .0001), and comorbidities (Charlson Comorbidity index= 3.9 vs. 3.3, p< .0001). Of 
2,558 treated CHC patients, patients were treated by SOF/IFN/RBV (n= 580), SOF/RBV 
(n= 587), SOF/SMV (n= 511), INF/RBV (n= 342), BOC/IFN/RBV (n = 83), TEL/IFN/RBV 
(n = 162), and other regimens (n= 293). Across all the regimens, the mean age ranged 
from 53-59 years, and majority were male (60%-69%). Among patients receiving SOF/
IFN/RBV, SOF/RBV, SOF/SMV, INF/RBV, BOC/IFN/RBV or TEL/IFN/RBV therapy, cirrhosis 
was observed in 31%, 43%,55%,32%, 37%, and 28% respectively (p< 0.001). While the 
majority of patients treated with BOC/IFN/RBV (90%) or INF/RBV (69%) were HCV 
treatment experienced, only ~10% of patients with SOF-based regimen had prior 
HCV treatment (p< .0001). Patients treated with SOF/SMV had significantly more 
comorbidities compared to other regimens (p< 0.001); 13% of had prior liver trans-
plants compared to 7% of both SOF/RBV and INF/RBV patients and 2% of SOF/IFN/
RBV (p< .0001). ConClusions: In an insured population, treated CHC patients had 
higher rates of comorbidities and cirrhosis compared to untreated patients. While 
the majority of CHC patients with SOF-based regimen were treatment naïve, patients 
treated with SOF/SMV had higher comorbidities compared to other regimens.
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objeCtives: To compare patient characteristics and drug utilization among 
CHC patients with and without CKD in a US treated CHC population. Methods: 
De-identified, individual-level healthcare claims data from Truven Health 
MarketScan® database was analyzed. CHC was defined as those who had ≥ 2 medi-
cal claims of HCV (ICD9: 070.54, 070.44, 070.70, 070.71) ≥ 1 month apart. Three-year 
continuous enrollment was required in order to capture prior treatment experience. 
The CHC treated cohort was defined as those who had at least 1 HCV medica-
